openPR Logo
Press release

Viral Vectors and Plasmid DNA Manufacturing Market Key Developments, Footprint with Top companies Kaneka Eurogentec S.A., FinVector, Brammer,Sanofi, Spark Therapeutics, Cobra Biologics

Viral Vectors and Plasmid DNA Manufacturing

Viral Vectors and Plasmid DNA Manufacturing

Viral vector and plasmid DNA manufacturing plays a major role in modern healthcare, as it reduces disease management price by generating a wider range of immune response types and supporting to decrease the periodic medication dosage.

The global viral vector and plasmid DNA manufacturing market size was valued at US$ 290.0 million in 2017, and is expected to exhibit a CAGR of 22.5% over the forecast period (2018 – 2026).

Viral vector and plasmid DNA manufacturing is used in application of gene therapy to diagnose and treat diseases in patients. High prevalence of cancer is expected to propel demand for gene therapy, which in turn is expected to drive the market growth. According to World Health Organization (WHO), 2012, cancer is the second leading cause of morbidity and mortality worldwide, with around 14 million new cases registered in 2012, and was responsible for 8.8 million deaths worldwide in 2015. Moreover, WHO stated that, the number of new cases of cancer is expected to rise by around 70% by the end of 2030.

Similarly, according to the International Quarterly Journal of Research in Ayurveda, published in 2010, estimated around 20 – 30% of all infant deaths are due to genetic disorders, and around 11.1% of pediatric hospital admissions are for children with inherited disorders. Furthermore, rising awareness regarding gene therapy is propelling growth of the viral vector and plasmid DNA manufacturing market over the forecast period. For instance, in November 2018, the National Institutes of Health (NIH) launched a new initiative to accelerate adoption of gene therapy to cure around 20 million patients diagnosed with sickle cell disease.

Request A Sample Copy:
https://www.coherentmarketinsights.com/insight/request-sample/962

However, complications such as risk of mutagenesis, safety and efficacy issues, and stringent regulatory framework are expected to limit the adoption of gene therapy, thereby hindering the market growth.

North America holds a dominant position in the global viral vector and plasmid DNA manufacturing market, owing to high prevalence of viral infection in the region. According to the National Center for Biotechnology Information (NCBI) report, published in December 2017, around 98 cases diagnosed with Powassan Virus were reported from 1999 to 2016, with an increase of 671% cases from 1999 to 2016.

Moreover, increasing research and development activities in the field of viral vector and plasmid DNA manufacturing is expected to enhance its demand in the near future. For instance, in April 2017, Transgene announced plans for a new clinical research collaboration of investigational therapeutic vaccine TG4010 in combination with Bristol-Myers Squibb’s Opdivo (nivolumab) with standard chemotherapy (CT) as a first-line treatment for advanced non-squamous, non-small cell lung cancer (NSCLC) in patients, which is under Phase 2 clinical trial.

Key Players

Major players operating in the global viral vector and plasmid DNA manufacturing market include, Kaneka Eurogentec S.A., FinVector, Brammer Bio, Cell and Gene Therapy Catapult, Transgene SA, FUJIFILM Diosynth Biotechnologies, Sanofi, Spark Therapeutics, Cobra Biologics, UniQure, MassBiologics, 4D Molecular Therapeutics, Renova Therapeutics, Shenzhen SiBiono GeneTech Co., Ltd., and Thermo Fisher Scientific, Inc.

Viral vector and plasmid DNA is product of gene therapy, which is used in diagnosis and treatment of diseases such as cancer, inherited diseases, viral infections, and others. The therapeutic DNA is introduced in host with the help of a vector. Adeno associated virus based vector are much safer as compared with others viral vectors due to its integration at same site in human genome, and has wide application in various disorders such as Alzheimer’s disease.

Market Dynamics

Increasing prevalence of cancer is a major factor driving growth of the viral vector and plasmid DNA manufacturing market. According to World Cancer Research Funds and the American Institute for Cancer Research, in 2018, there were around 18 million cases of cancer, of which around 9.5 million were in men and around 8.5 million in women, globally. Moreover, government and other organizations’ initiatives regarding awareness of gene is expected to boost growth of the market. For instance, in June 2018 Alliance for Regenerative Medicine launched ARM Foundation for Cell and Gene Medicine to educate, empower, and engage public about cell and gene medicine as a treatment option. The foundation will accelerate patient’s access to safe and curative gene therapies.

However, safety and efficacy issues, stringent regulatory framework and risk of mutagenesis are expected to limit the adoption if gene therapy, thereby hindering the market growth. For instance, some viral vectors, such as gamma-retroviruses, insert its genomes at random location on the host chromosomes, which can lead to cancer.

Download the PDF brochure:
https://www.coherentmarketinsights.com/insight/request-pdf/962

About Coherent Market Insights:
Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:
Mr.Shah
Coherent Market Insights
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email:sales@coherentmarketinsights.com

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Viral Vectors and Plasmid DNA Manufacturing Market Key Developments, Footprint with Top companies Kaneka Eurogentec S.A., FinVector, Brammer,Sanofi, Spark Therapeutics, Cobra Biologics here

News-ID: 1738214 • Views: 463

More Releases from Coherent Market Insights - Biotechnology

Recombinant Protein Market To Witness Robust Expansion Throughout The Forecast P …
Recombinant proteins have immense potential in cancer therapy research and development. For instance, growth factors, immune checkpoint, and cell damage & oxidative stress proteins (preclinical stage) are utilized from recombinant proteins category for cancer therapy research. Increased understanding of oncogenic signaling pathways and proteins involved in the same has increased the targeting ways, wherein, recombinant proteins such as immune checkpoint, growth factors, and antibodies are used. These proteins are used
Biosimilar Pipeline Analysis Market Outlook 2019: Rapidly Develop by key Players …
Biosimilar market is under the initial phase of development, they are used for the treatment of various disorders such as autoimmune disease, cancer as per National Institute of Health 2012 report, there were more than 23.5 million people living with autoimmune disease in the U.S. and low pricing of biosimilar drugs make them affordable for people. The same mechanism of action provides effective treatment for disease along with increased awareness
Cancer Biomarkers Market Rapid Growth 2019 by leading players BioMerieux S.A., B …
The global cancer biomarkers market is projected to witness significant growth over the forecast period, owing to rising incidence and prevalence of various cancer types, including breast cancer, lung cancer, kidney cancer, liver cancer, prostate cancer, and among others. Moreover, other factors impacting growth of cancer biomarkers market includes rising research and development activities in developing cancer biomarker and rising demand for personalized medicine in cancer therapies. Free Request Sample Copy
Diabetes Vaccine Market Scrutinized in New Research 2018-2026
Diabetes is one of most prevalent chronic diseases worldwide. According to WHO (World Health Organization), diabetes was one of top three leading causes of mortality in 2012. The diabetes vaccine currently under development has significant potential in younger age group (Below 20 years age), who are characterized by a stronger autoimmune response to combat infection from specific viruses. Diabetes vaccine is being developed to strengthen the body’s response against enterovirus

All 5 Releases


More Releases for DNA

Recombinant DNA Technology Market -
Recombinant DNA technology has allowed the transfer of desired characteristics which is useful to improve the existing systems by controlling expression of target genes. Recombinant DNA technology allows mass production of therapeutic proteins, which are characterized by high level of consistency and stability. The technology has multidisciplinary applications and potential to deal with important aspects of life, for instance, improving health, and enhancing food resources. The genetically modified plants have
Synbio Technologies Revolutionizes DNA Synthesis
DNA Synthesis Definition and Methods DNA synthesis definition DNA synthesis is defined as the process by which copies of nucleic acids are strung together to form a longer DNA sequence within a laboratory setting. DNA synthesis processes DNA oligomers are the foundation of the DNA synthesis process. The essential feature of DNA synthesis is that no naturally isolated DNA is used. This step deviates from the traditional method of studying genetics, by which a
Global DNA Vaccine Pipeline Analysis
he global market for DNA vaccines is currently recording significant growth rates owing to the lesser side effects, ease of development, lesser cost and continued development in biotechnology arena. At present, not even a single DNA vaccine has been approved for human beings. However, around 100 products are under clinical trial for treating diseases like HIV infection, cancer and other infectious diseases. With regards to animal health, there are three
Global DNA Sequencing Market Report
MarketResearchReports.Biz announces addition of new report “Global DNA Sequencing Market Report: 2015 Edition” to its database. Description DNA sequencing market is one of the fastest growing segments of the life sciences tools market. This research study includes the market assessment of various products, technologies, applications and end-users. The report briefs about the classification in genomics, process of transcription and translation of DNA, historical development, and generations of sequencing technologies. The sequencing industry is
Global DNA Sequencing Market Report
MarketResearchReports.Biz announces addition of new report “Global DNA Sequencing Market Report: 2015 Edition” to its database. Description DNA sequencing market is one of the fastest growing segments of the life sciences tools market. This research study includes the market assessment of various products, technologies, applications and end-users. The report briefs about the classification in genomics, process of transcription and translation of DNA, historical development, and generations of sequencing technologies. The sequencing industry is
DNA Chip and DNA microarray industry NextGen Frontier for DNA Technologies – I …
A report from Transparency Market Research, titled ‘DNA Chip Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2015 – 2023,’ states that the global DNA chip market is expected to expand at a rapid pace during the period from 2015 to 2023 due to the increasing prevalence of cancer, the growth in personalized medicines, and technological advancements. A DNA chip, also known as a DNA microarray,